Navigation Links
1/5 of British adult survivors of childhood cancer smoke despite hazards
Date:7/29/2008

treatment.

More needs to be done to reduce the rate of smoking in adult cancer survivors, Emmons writes, noting that fewer than half of the survivorship programs in the U.S. currently offer smoking cessation services. Beyond just treating this issue specifically, however, Emmons argues that broader efforts are needed to improve the socioeconomic pressures and social disadvantages that encourage smoking and reduce public health. "It is time to think well beyond our disciplinary boundaries and implement interventions that we know are efficacious, such as provider-delivered counseling and pharmacotherapy, and seek solutions for the social conditions that serve as a trajectory for a lifetime of smoking," she writes.


'/>"/>

Contact: Liz Savage
elizabeth.savage@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. British Council and Los Angeles Area Universities Partner to Host Transatlantic Dialogues
2. New Study Data Published in British Journal of Urology Demonstrates Cryoablation Effective for Kidney Cancer
3. British Royal highlights anesthesia crisis in the developing world
4. Boiron Laboratories Disputes British Journals Editorial on Homeopathy
5. University of British Columbia Research Shows Health Benefits of GameBike (TM)
6. Surgery Holidays to Malaysia - British Women Tell Their Stories
7. Gliding to gold -- world-beating software could boost British swimming
8. Hospital for Special Surgery shares best practices to benefit of British patients
9. Americas StriVectin the Only Great Serum for Mature, Aging Complexions, Says Leading British Newspaper
10. Bounty Poll Reveals British Mums in the Dark Over Bisphenol-A in Baby Bottles
11. British showers most wasteful and inconsiderate in Western Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... September 01, 2015 , ... The PT Outcomes Registry is an ... for physical therapy patients. The Registry is being developed by the American Physical Therapy ... are happy to be selected to contribute FOTO Outcomes measures as one of the ...
(Date:8/31/2015)... ... August 31, 2015 , ... ITC Global Translations website, ... for specific translation services within the medical and pharmaceutical industries. These are industries ... successful work. , ITC Global Translations specializes in professional translation services for materials ...
(Date:8/31/2015)... ... August 31, 2015 , ... India Network Foundation, ... InstantQuote ” tool, which summarizes all available plans, plan maximums, pre-existing condition coverage ... designed to help India Network members make an informed decision regarding the care ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... postnatal fitness classes. , Starting September 1st they are offering pre ... Mom Bod" and "Healthy Body, Healthy Baby." , More information can be found ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Sundance Film Festival award winning ... 1. , “Alive Inside” shadows a social worker who advocates for the use of ... documentary about bringing music to residents in health care centers who may have lost ...
Breaking Medicine News(10 mins):Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2
... , ASHEVILLE, N.C. , Jan. ... and smart companies are working hard to adjust their recipes to find ... is one option that is all natural, low in sodium—40% to 70% ... the first and only natural low sodium sea salt. Total sales that ...
... , St. Jude Children,s Research Hospital scientists lead effort ... host of bacterial toxins , MEMPHIS, Tenn. , ... of widely used cholesterol-lowering drugs might help protect individuals from ... pose a deadly threat to those with sickle cell disease. ...
... Acknowledging that the idea of rationing health care, particularly at ... get much rational consideration, a Johns Hopkins emeritus professor of ... an opinion piece featured in this month,s issue of the ... article, John Freeman, M.D., Lederer Professor Emeritus of Pediatric Neurology ...
... from forming, research shows , TUESDAY, Jan. 19 (HealthDay News) ... tobacco known as NNK contributes to the formation of lung ... Taiwan report that NNK contributes to the accumulation of a ... DNMT1 turns off genes that keep tumors from forming. ...
... chromosome lineage reveals farming influence , TUESDAY, Jan. 19 (HealthDay ... farmers who migrated from the Near East 10,000 years ago, ... Y chromosome, which is passed from father to son. , ... by about 110 million men -- it follows a gradient ...
... ... ALS (amyotrophic laterals sclerosis) announced today that it has appointed Gordon S. LaVigne as ... ... ALS Association , the nation’s leader in the fight against the disease ALS ...
Cached Medicine News:Health News:Ocean's Flavor Natural Sea Salt is Helping Companies Reach Low Sodium Goals 2Health News:Ocean's Flavor Natural Sea Salt is Helping Companies Reach Low Sodium Goals 3Health News:Cholesterol-Lowering Drug Shows Promise Against Serious Infections in Sickle Cell Disease 2Health News:Cholesterol-Lowering Drug Shows Promise Against Serious Infections in Sickle Cell Disease 3Health News:Cholesterol-Lowering Drug Shows Promise Against Serious Infections in Sickle Cell Disease 4Health News:Cholesterol-Lowering Drug Shows Promise Against Serious Infections in Sickle Cell Disease 5Health News:Reasoning through the rationing of end-of-life care 2Health News:Gordon S. LaVigne Appointed ALS Association Chief Development and Communications Officer , 2Health News:Gordon S. LaVigne Appointed ALS Association Chief Development and Communications Officer , 3
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: